Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.

Status:
Completed

Trial end date:
2013-10-01

Target enrollment:

Participant gender:

Study to determine the Maximum Tolerated dose of BIBW 2992 given in combination with Herceptin®

Phase 1

Boehringer Ingelheim

Afatinib
Trastuzumab